Bone Density Increase After Starting Prolia (Denosumab)

Factors Affecting BMD Response

• Adequate calcium and vitamin D supplementation is essential to support bone mineralization during denosumab therapy, as recommended by the American Society of Clinical Oncology 3, 4
• Weight-bearing exercise and resistance training can complement the effects of denosumab on bone density, according to the American College of Sports Medicine 3, 1

Clinical Considerations

• Hypocalcemia is a potential side effect of denosumab, making calcium and vitamin D supplementation crucial, as noted by the National Osteoporosis Foundation 2
• Regular monitoring of BMD is recommended at 1-2 year intervals to assess treatment response, as suggested by the International Osteoporosis Foundation 2

Special Populations

• In men receiving androgen deprivation therapy (ADT) for prostate cancer, denosumab treatment for 36 months increased BMD by 6.7% at the lumbar spine and 4.8% at the total hip compared to placebo, as reported by the European Association of Urology 3, 4
• Denosumab has demonstrated superior efficacy in preventing vertebral fractures in men on ADT compared to other treatments, according to the American Urological Association 5

Caution

• Discontinuation of denosumab without follow-up antiresorptive therapy can lead to rapid bone loss and increased fracture risk, so continuous therapy or transition to another antiresorptive is important, as warned by the American College of Rheumatology 2